Mesenchymal Stromal Cells Fail to Alleviate Experimental Graft-Versus-Host Disease in Rats Transplanted with Major Histocompatibility Complex-Mismatched Bone Marrow

被引：9

作者：

Zinocker, S. ^{[1
,2
]}

Wang, M. -Y. ^{[3
]}

Rolstad, B. ^{[2
]}

Vaage, J. T. ^{[1
]}

机构：

[1] Natl Hosp Norway, Oslo Univ Hosp, Dept Immunol, N-0424 Oslo, Norway

[2] Univ Oslo, Inst Basic Med Sci, Dept Anat, Oslo, Norway

[3] Norwegian Radium Hosp, Oslo Univ Hosp, Inst Tumor Biol, Oslo, Norway

来源：

SCANDINAVIAN JOURNAL OF IMMUNOLOGY | 2012年 / 76卷 / 05期

关键词：

D O I：

10.1111/j.1365-3083.2012.02758.x

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Mesenchymal stromal cells (MSC) can be used to treat graft-versus-host disease (GVHD) caused by allogeneic stem cell transplantation (allo-SCT). The effectiveness of this therapy has been variable in clinical trials and in experimental animal models. In this study, we investigated the ability of bone marrow (BM)-derived MSC to alleviate GVHD in an experimental rat model of allo-SCT using two different combinations of major histocompatibility complex (MHC) mismatch with survival as the primary endpoint. Recipient rats received total body irradiation and a transplant of T cell-depleted donor BM cells with either a full [PVG.7B ? BN] or a partial MHC mismatch [PVG.1U ? PVG.R23] restricted to the class II and non-classical class I sub-regions (RT1-B/D-CE/N/M). GVHD was invoked by infusion of graded doses of donor leukocytes 2 weeks after allo-SCT. Weekly doses of MSC were injected starting on the day of donor leukocyte infusion. No significant overall improvement of mortality and morbidity was observed in the two transplantation settings. Stimulation of MSC with exogenous tumor necrosis factor a and interferon (IFN)? prior to infusion could not rescue BM-transplanted rats from lethal acute GVHD. In conclusion, repeated administrations of MSC failed to alleviate GVHD after fully or partially MHC-mismatched allo-SCT in the rat.

引用

页码：464 / 470

页数：7

共 40 条

[1]

Appelbaum F.R., Haematopoietic cell transplantation as immunotherapy, Nature, 411, pp. 385-389, (2001)

[2]

Kolb H.-J., Graft-versus-leukemia effects of transplantation and donor lymphocytes, Blood, 112, pp. 4371-4383, (2008)

[3]

Ferrara J.L.M., Levine J.E., Reddy P., Holler E., Graft-versus-host disease, Lancet, 373, pp. 1550-1561, (2009)

[4]

Kebriaei P., Robinson S., Treatment of graft-versus-host-disease with mesenchymal stromal cells, Cytotherapy, 13, pp. 262-268, (2011)

[5]

Aggarwal S., Pittenger M.F., Human mesenchymal stem cells modulate allogeneic immune cell responses, Blood, 105, pp. 1815-1822, (2005)

[6]

Bartholomew A., Sturgeon C., Siatskas M., Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo, Exp Hematol, 72, pp. 1653-1655, (2002)

[7]

Di Nicola M., Carlo-Stella C., Magni M., Et al., Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or non-specific mitogenic stimuli, Blood, 99, (2002)

[8]

Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide, Blood, 101, pp. 3722-3729, (2003)

[9]

Maitra B., Szekely E., Gjini K., Et al., Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation, Bone Marrow Transplant, 33, pp. 597-604, (2004)

[10]

Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C., Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation, Transplantation, 75, pp. 389-397, (2003)

← 1 2 3 4 →